Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans
August 21, 2024 07:57 ET
|
Aclarion, Inc.
Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After Receiving Nociscan Data Multiple Physicians and Sites Will Enroll in CLUE...
Aclarion Announces First Commercial Agreement in Michigan
August 14, 2024 08:08 ET
|
Aclarion, Inc.
Sheridan Community Hospital is the First Healthcare Institution in Michigan With Nociscan Agreement Expands Nociscan Access to John Keller, MD, a Leading Neurosurgeon and Aclarion Medical Advisor,...
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
July 09, 2024 07:00 ET
|
Aclarion, Inc.
Aviva is a Top 4 Provider of Private Medical Insurance in the UK By Joining AXA, Approximately 45% of Patients With Private Insurance Now Have Access to Nociscan in the Greater London Spine Care...
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK
June 26, 2024 08:30 ET
|
Aclarion, Inc.
AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage is the Most Important Catalyst Aclarion can Achieve to Drive Volume and Revenue AXA Represents the First...
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London
June 25, 2024 08:30 ET
|
Aclarion, Inc.
Established in 1932, the London Clinic is the UK’s Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract...
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs
March 04, 2024 08:00 ET
|
Aclarion, Inc.
Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting...
Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution
January 17, 2024 08:00 ET
|
Aclarion, Inc.
Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine This new product release expands accessibility of Nociscan on the worldwide MR market Builds...
Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan
January 08, 2024 08:00 ET
|
Aclarion, Inc.
Partnership aims to include Aclarion’s surgical decision support technology within ATEC’s AlphaInformatiX platform to better inform spine surgery Aclarion’s Nociscan is the first augmented...
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
November 08, 2023 08:00 ET
|
Aclarion, Inc.
Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care....
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
October 25, 2023 08:30 ET
|
Aclarion, Inc.
Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain George...